eISSN: 2373-6372 GHOA

Gastroenterology & Hepatology: Open Access
Volume 4 Issue 3 - 2016
Long-Time Gastric Protection
Nelson Carrillo*
Department of Gastroenterology, University of Venezuela, Venezuela
Received: January 13, 2016 | Published: February 22, 2016
*Corresponding author: Nelson Carrillo, Department of Gastroenterology, University of Venezuela, Libertador Avenue, Angostura Building, 7 Floor, Office 7B, Caracas, Venezuela, Tel: 58-212-7632202; Fax: 58-212-9917903; Email:  &
Citation: Carrillo N (2016) Long-Time Gastric Protection. Gastroenterol Hepatol Open Access 4(3): 00098. DOI:10.15406/ghoa.2016.04.00098


“Gastricprotection” has popularized the use of proton pump inhibitors (PPI) and often are used for any reason without medical control, like after a heavy alcohol intake, in mild heart burn or dyspepsia. The drugs used are Omeprazol, Lanzoprazol, Esemeprazol etc. These drugs decline the acid secretion of the stomach as the main effect. Many people use them at their convenience. Some manufacters has recommended “manteinance dose” for months and years, this is not convenient. Their sales in USA are $10.billion in 2001 and $ 13.8 billions in 2008, is the drug most sold in the world [1].

They are used in routine hospitalization and 65-70 % did not need it and are used as unnecessary mantainance dose too [2]. It has been reported that bloking the gastric secretion leads to pneumonia and bronchopneumonia because bacteria are not destroyed [3]. Prolonged use of PPIs affect the absorption of vitamin B12. Its use by more tan 6 months increase Clostridium Difficile disease of 5 to 23 % [4,5]. There have been case reports implicating these drugs in acute intestitial nephritis and progression to acute renal failure [6].


The PPIs should de used for a maximun of 6-8 weeks as illness required, a large number of patients are taking PPIs for no clear reason. PPIs should be stopped to determinate if symptomatic treatment is needed.


  1. Forgacs I, Loganayagam A (2008) Overprescribing proton pump inhibitors. BMJ 336(7634): 2-3.
  2. Nardino RJ, Vender RJ, Herbert PN (2000) Over use of acid supressive therapy in hospitalized patients. Am J Gast 95(11): 3118-3122.
  3. Laheij RJ, Sturkenboom MC, Hassing RJ, Dieleman J, Stricker BH, et al. (2004) Risk of community-adquired pneumonia and use of gastric supressive drugs. JAMA 292(16):1955-1960.
  4. Savarino V, Di Mario F, Scarpignato C (2009) Proton pump inhibitors in GORD-An overview of the pharmacology and safety. Phamacol Res 59(3): 135-153.
  5. Dalton BR, Lye-Maccannell T, Henderson EA, Maccannell DR, Louie TJ (2009) Proton pump inhibitors increase significantly the risk of Clostridium difficile infection in a low-endemicity, non-outbreak hospital setting. Phanacol Ther 29(6): 626-634.
  6. Geevasinga N, Coleman PL, Webster AC, Roger SD (2006) Proton pump inhibitors and acute interstitial nephritis. Clin Gastroenterol Hepatol 46(5): 597-604.
© 2014-2019 MedCrave Group, All rights reserved. No part of this content may be reproduced or transmitted in any form or by any means as per the standard guidelines of fair use.
Creative Commons License Open Access by MedCrave Group is licensed under a Creative Commons Attribution 4.0 International License.
Based on a work at https://medcraveonline.com
Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version | Opera |Privacy Policy